AbbVie (ABBV) Accounts Payables (2012 - 2026)

AbbVie has disclosed Accounts Payables across 15 years of filings, most recently posting $33.8 billion for Q1 2026.

• In Q1 2026, Accounts Payables rose 8.8% year-over-year to $33.8 billion; the TTM figure through Mar 2026 stood at $33.8 billion (up 8.8% YoY), while the FY2025 annual figure was $34.7 billion, up 8.73% from the prior year.
• Accounts Payables fell to $33.8 billion in Q1 2026, from $34.7 billion in the prior quarter.
• Over the last five years, Accounts Payables for ABBV reached as high as $34.7 billion in Q4 2025 and fell as low as $22.5 billion in Q2 2022.
• The 5-year median for Accounts Payables is $30.5 billion (2024), against an average of $29.1 billion.
• Annual changes were most pronounced in 2024 — Accounts Payables gained 26.37% — and 2025, when it decreased 0.91%.
• A 5-year view of Accounts Payables shows it stood at $25.4 billion in 2022, then increased by 20.66% to $30.6 billion in 2023, then increased by 4.23% to $31.9 billion in 2024, then advanced by 8.73% to $34.7 billion in 2025, then retreated by 2.76% to $33.8 billion in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $33.8 billion, $34.7 billion, and $33.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.